高分化神经内分泌肿瘤（NET）过度表达生长抑素受体，这是肽受体放射性核素治疗（PRRT）的靶点。 NET 生长速度缓慢，可转移至肝脏、骨骼和肺部。在 NET 患者中，肝转移是一个重要的预后标志，因为肝衰竭是该人群最常见的死亡原因之一。在这方面，我们的目的是描述接受 177Lu-DOTATATE PRRT 的患者实验室参数的变化，重点是肝脏参数。 100 名患者接受 1 至 4 个周期的 7.4 GBq (200 mCi) 177Lu-DOTATATE 治疗这项回顾性观察性单中心研究对 2011 年 1 月至 2021 年 12 月进行了分析。每个 PRRT 周期之前和之后对患者进行血液检查。收集实验室测量结果以评估肝功能、胆汁淤积、肾脏和骨髓功能。在一般人群 (n = 110) 中，ALP (P = 0.013) 和 GGT (P < 0.001) 显示出统计学上显着的降低。肝病体积高的患者的 ALT 显着降低（P = 0.016），而肝病体积低的患者的 GGT 显着降低（P = 0.013）。骨髓功能的所有参数在所有人群亚群中均显示出统计上显着的下降。接受 177Lu-DOTATATE 治疗的患者显示出肝功能和胆汁淤积参数显着改善，并且骨髓功能持续下降，即使存在晚期肝病.版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Well-differentiated neuroendocrine neoplasms (NETs) overexpress the somatostatin receptor, which is the target for the peptide receptor radionuclide therapy (PRRT). NETs have a slow growth rate and can metastasize to liver, bone, and lungs. In NETs patients, liver metastasis is an important prognostic marker because liver failure is one of the most common causes of death in this population. In this regard, we aimed to describe the changes in laboratorial parameters in patients submitted to PRRT with 177Lu-DOTATATE, focusing on hepatic parameters.One hundred ten patients treated with 1 to 4 cycles of 7.4 GBq (200 mCi) of 177Lu-DOTATATE from January 2011 to December 2021 were analyzed in this retrospective observational single-center study. Patients were submitted to blood tests before and after each cycle of PRRT. Laboratory measurements were collected to assess liver function, cholestasis, kidney, and bone marrow function.In the general population (n = 110), ALP (P = 0.013) and GGT (P < 0.001) showed a statistically significant reduction. Patients with high liver disease volume showed a statistically significant reduction in ALT (P = 0.016), whereas patients with low liver disease volume showed a statistically significant reduction in GGT (P = 0.013). All parameters for bone marrow function showed a statistically significant decrease in all population subsets.Patients treated with 177Lu-DOTATATE showed a significant improvement in liver function and cholestasis parameters, and a consistent decrease in bone marrow function, even in the presence of advanced liver disease.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.